Enanta Pharmaceuticals Inc (ENTA)
12.92
+0.16
(+1.25%)
USD |
NASDAQ |
May 09, 15:35
Enanta Pharmaceuticals Price to Book Value: 1.424 for May 9, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 08, 2024 | 1.407 |
| May 07, 2024 | 1.444 |
| May 06, 2024 | 1.610 |
| May 03, 2024 | 1.673 |
| May 02, 2024 | 1.534 |
| May 01, 2024 | 1.495 |
| April 30, 2024 | 1.515 |
| April 29, 2024 | 1.461 |
| April 26, 2024 | 1.364 |
| April 25, 2024 | 1.376 |
| April 24, 2024 | 1.424 |
| April 23, 2024 | 1.450 |
| April 22, 2024 | 1.482 |
| April 19, 2024 | 1.469 |
| April 18, 2024 | 1.459 |
| April 17, 2024 | 1.544 |
| April 16, 2024 | 1.694 |
| April 15, 2024 | 1.781 |
| April 12, 2024 | 1.814 |
| April 11, 2024 | 1.847 |
| April 10, 2024 | 1.824 |
| April 09, 2024 | 1.854 |
| April 08, 2024 | 1.804 |
| April 05, 2024 | 1.820 |
| April 04, 2024 | 1.784 |
| Date | Value |
|---|---|
| April 03, 2024 | 1.842 |
| April 02, 2024 | 1.803 |
| April 01, 2024 | 1.876 |
| March 28, 2024 | 1.925 |
| March 27, 2024 | 1.822 |
| March 26, 2024 | 1.759 |
| March 25, 2024 | 1.537 |
| March 22, 2024 | 1.609 |
| March 21, 2024 | 1.613 |
| March 20, 2024 | 1.599 |
| March 19, 2024 | 1.548 |
| March 18, 2024 | 1.490 |
| March 15, 2024 | 1.567 |
| March 14, 2024 | 1.528 |
| March 13, 2024 | 1.592 |
| March 12, 2024 | 1.603 |
| March 11, 2024 | 1.663 |
| March 08, 2024 | 1.698 |
| March 07, 2024 | 1.733 |
| March 06, 2024 | 1.727 |
| March 05, 2024 | 1.660 |
| March 04, 2024 | 1.726 |
| March 01, 2024 | 1.692 |
| February 29, 2024 | 1.584 |
| February 28, 2024 | 1.577 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
0.7948
Minimum
Nov 13 2023
4.955
Maximum
Nov 05 2021
2.534
Average
2.332
Median
Price to Book Value Benchmarks
| Madrigal Pharmaceuticals Inc | 10.13 |
| Galectin Therapeutics Inc | -- |
| Viking Therapeutics Inc | 9.494 |
| Akero Therapeutics Inc | 2.678 |
| 89bio Inc | 1.619 |
Price to Book Value Related Metrics
| PS Ratio | 3.696 |
| PEG Ratio | -0.1549 |
| Price | 12.92 |
| Earnings Yield | -50.77% |
| Market Cap | 273.34M |
| PEGY Ratio | -0.1549 |